Equities

Mayinglong Pharmaceutical Group Co Ltd

600993:SHH

Mayinglong Pharmaceutical Group Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (CNY)23.32
  • Today's Change0.16 / 0.69%
  • Shares traded4.51m
  • 1 Year change-10.86%
  • Beta1.2574
Data delayed at least 15 minutes, as of Mar 13 2024 07:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Mayinglong Pharmaceutical Group Co., Ltd. is a China-based company, principally engaged in pharmaceutical production, retailing and wholesaling businesses. The Company's pharmaceutical products are classified as drugs for hemorrhoid, including diosmin tablets, suppositories, pastes and granules, among others; drugs for cough, including levodropropizine oral solution and compound glycyrrhiza oral solution, as well as drugs for skin injuries, including products such as erythromycin ointment. The Company also provides specialty drugs. The Company is also engaged in the production and distribution of eye cream products with the brand named Mayinglong BaBao, as well as the provision of hospital clinical service. The Company distributes its products mainly in domestic markets.

  • Revenue in CNY (TTM)3.26bn
  • Net income in CNY453.31m
  • Incorporated1994
  • Employees2.88k
  • Location
    Mayinglong Pharmaceutical Group Co LtdNo. 100, Nanhu Zhoujiawan, WuchangWUHAN 430064ChinaCHN
  • Phone+86 2 787291519
  • Fax+86 2 787291724
  • Websitehttps://www.mayinglong.cn/index.html
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Nanjing Vazyme Biotech Co Ltd1.29bn-15.12m11.18bn2.70k--2.78--8.70-0.0368-0.03683.2710.070.21910.97612.85476,061.10-0.28613.16-0.372415.9271.3170.50-1.3123.922.97--0.215432.20-63.9749.74-111.94--48.61--
Joinn Laboratories China Co Ltd2.33bn-62.99m11.33bn2.50k--1.52--4.86-0.0862-0.08623.1210.750.230.69068.14---0.68568.99-0.821911.0739.4646.76-2.9832.013.510.99960.007923.794.7842.20-63.0429.668.2123.46
Heilongjiang ZBD Pharmaceutical Co Ltd2.73bn511.96m11.41bn2.55k22.231.45--4.180.54470.54472.908.350.21861.580.81341,071,832.004.063.485.614.7846.0938.9318.5610.082.35--0.286227.18-25.502.45155.000.4417-25.684.05
Jiangsu Kanion Pharmaceutical Co., Ltd.4.87bn543.34m11.47bn5.44k21.002.13--2.350.93420.93428.399.220.69153.506.92895,523.307.826.6810.549.4972.5574.0211.3110.282.23--0.0025.5711.884.9423.545.33-1.8735.84
Liaoning Chengda Biotechnology Co Ltd1.76bn420.34m11.78bn1.73k27.901.21--6.691.011.014.2623.410.17430.70611.611,016,911.004.1610.634.2711.0181.4885.7423.8739.5620.80--0.00231.53-3.584.71-34.75-5.5639.78--
Jiangsu Sinopep Allsin Bphrmctcl Co Ltd1.18bn208.25m11.94bn1.55k57.365.31--10.110.97690.97695.5410.550.37431.214.71764,598.406.695.869.157.5963.1555.4117.8717.201.0833.770.335627.5958.6932.2426.2029.9927.32--
Mayinglong Pharmaceutical Group Co Ltd3.26bn453.31m12.00bn2.88k26.473.07--3.681.051.057.569.080.64825.8711.131,130,851.009.2610.8211.0313.4742.8741.1814.2914.085.18--0.072933.04-11.207.38-7.4620.2658.3321.67
Jiangxi Tianxin Pharmaceutical Co Ltd1.80bn514.80m12.03bn2.47k23.332.76--6.691.181.184.119.950.362.686.66727,792.6010.31--11.11--39.78--28.63--5.51--0.0551---18.34---23.51------
Sansure Biotech Inc1.20bn384.73m12.04bn2.01k31.731.60--10.010.64480.64482.0612.770.13770.82741.41599,646.904.1426.744.6930.9774.8267.4730.0642.017.94--0.058922.40-84.3927.12-81.22121.8964.08--
Zhejiang CONBA Pharmaceutical Co., Ltd.6.43bn523.43m12.70bn8.41k24.451.78--1.980.2020.2022.492.780.55682.394.60764,058.905.026.777.2510.5054.3663.249.0211.101.5340.710.145942.3212.20-0.826765.20-6.21-11.645.92
Data as of Mar 13 2024. Currency figures normalised to Mayinglong Pharmaceutical Group Co Ltd's reporting currency: Chinese Yuan Renminbi CNY

Institutional shareholders

10.20%Per cent of shares held by top holders
HolderShares% Held
Bank of Communications Schroder Fund Management Co., Ltd.as of 30 Jun 202312.69m2.95%
China Universal Asset Management Co., Ltd.as of 30 Jun 20238.28m1.92%
CITIC Securities Co., Ltd. (Invt Port)as of 30 Jun 20235.29m1.23%
Zhong Ou Asset Management Co., Ltdas of 30 Jun 20234.02m0.94%
China Southern Asset Management Co., Ltd.as of 30 Jun 20233.04m0.71%
First-Trust Fund Management Co., Ltd.as of 30 Jun 20232.97m0.69%
Caitong Securities Asset Management Co., Ltd.as of 30 Jun 20232.50m0.58%
HuaAn Fund Management Co., Ltd.as of 30 Jun 20232.12m0.49%
Bank of China Investment Management Co., Ltd.as of 30 Jun 20231.55m0.36%
Wanjia Asset Management Co., Ltd.as of 30 Jun 20231.43m0.33%
More ▼
Data from 30 Jun 2023 - 31 Mar 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.